The Pharmaletter
One To Watch
EVOQ Therapeutics
A biotech research company advancing a pipeline of disease-specific immune modulators to treat patients afflicted with autoimmune diseases.
EVOQ's technology platform utilizes a proprietary NanoDisc that has been optimized to deliver antigens to restore immune tolerance.
In January 2023, EVOQ announced a collaboration and licensing agreement with US biotech Gilead Sciences , to advance its proprietary technology for the treatment of rheumatoid arthritis and lupus.
Latest EVOQ Therapeutics News
18 January 2023
10 January 2023
18 January 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze